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A B ST R AC T 
 
 
Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome 
is a potentially life-threatening, idiosyncratic, acute adverse drug reaction. 
Fever, morbilliform cutaneous eruption, and eosinophilia are essential 
features for the diagnosis of this syndrome, along with significant 
multisystem involvement, hepatitis being the most common, followed by 
nephritis. The pathogenesis of DRESS syndrome is not yet fully understood. 
Several hypotheses have been proposed which support the involvement of 
an intricate interplay of multiple factors. We report a clinical case of DRESS 
syndrome with renal injury, induced by carbamazepine, in a patient with 
alcohol abstinence syndrome. In order to define the case, the RegiSCAR 
score and the Japanese Group score, used in the diagnosis of drug-induced 
hypersensitivity, were applied. DRESS syndrome is a potentially fatal 
disease, with a mortality that can reach up to 40% of cases. This condition 
endangers the patient's life by affecting the internal organs, mainly the liver, 
kidneys, heart, and lungs. Our case attempts to increase awareness among 
physicians about this serious disease and the importance of early diagnosis, 
especially since carbamazepine is a commonly used anticonvulsant drug.   
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Drug reaction with eosinophilia and systemic 
symptoms (DRESS) syndrome is a potentially life-
threatening, idiosyncratic, acute adverse drug reaction [1]. 
The incidence of this syndrome is estimated to range from 
1:1000 to 1:10000 of drug exposures [2]. The overall 
mortality rate of this disease is 10-20% [3], but there are 
studies that present higher mortality rates, up to 40% if 
organ failure is present [4]. Fever, morbilliform cutaneous 
eruption, and eosinophilia are essential features for the 
diagnosis of this syndrome, along with significant 
multisystem involvement, hepatitis being the most 
common, followed by nephritis [3]. Highly suggestive of 
this condition is latency between initial drug administration 
and specific symptom onset [5]. The pathogenesis of 
DRESS syndrome is not yet fully understood. Several 
hypotheses have been proposed which support the 
involvement of an intricate interplay of multiple factors 
such as: mutations in genes encoding drug detoxification 
enzymes leading to the accumulation of drug reactive 
metabolites, reactivation of human herpes virus 6 and 7, 
Epstein-Barr virus (EBV), cytomegalovirus (CMV), 
genetic predisposition associated with certain human 
leukocyte antigens (HLA), and immunological phenomena 
[6]. Common drugs associated with DRESS syndrome are 
anticonvulsants (such as carbamazepine, phenytoin) [7]. 
The first step in treating the disease is prompt recognition 
and early discontinuation of the drug involved [8]. 
Systemic glucocorticoid therapy, intravenous 
immunoglobulin, antiviral drugs, plasmapheresis, 
cyclosporine, and symptomatic treatment are part of the 
appropriate management of this pathology [3]. In DRESS 
syndrome patients, careful long-term follow-up is crucial 
and monitoring for autoimmune diseases is required [5]. 
Case Presentation 
A 46-year-old man was admitted to the Department of 
Internal Medicine with a history of high fever (40.1°C), 
diffuse pruritic morbilliform cutaneous eruption which had 
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been continuing over the last ten days. Two days before 
hospitalization, the patient's condition worsened, with 
edema affecting his face and hands. Approximately 6 
weeks before, treatment with carbamazepine and vitamin 
B supplements for his alcohol abstinence syndrome was 
initiated. The patient’s medical history was notable for 
alcohol abuse, alcoholic steatosis, mitral valve 
regurgitation, and pulmonary tuberculosis. It is also 
important to mention that, prior to hospitalization, the 
patient underwent antibiotic treatment with ampicillin. 
On physical examination, his consciousness was clear 
and his general status was moderate, with a body 
temperature of 39.3°C, a heart rate of 100 beats per minute, 
a blood pressure of 100/70 mmHg, and an oxygen 
saturation of 99%. The patient had important edema of his 
face and hands, and a diffuse maculopapular erythematous 
eruption. He also had purpuric lesions on the lower 
extremities. There was no conjunctival involvement. At the 
time of admission, no palpable lymph nodes were 
identified. Apart from tachycardia, cardiovascular 
examination was normal. The respiratory system was clear 
bilaterally, without rhonchi or crackles. Digestive system 
examination revealed the presence of hepatomegaly. There 
were no signs of focal neurological deficits. 
On the day of the admission to our hospital, the patient 
was referred to an infectious disease specialist, who 
diagnosed him with acute pharyngitis, interstitial 
pneumonia, and polymorphous erythema, and prescribed 
treatment with antibiotics (macrolides: Azithromycin 500 
mg/day for 5 days or Clarithromycin 2x500 mg/day for 7 
days), antihistamines, and antipyretic drugs. He also 
recommended a chest X-ray and serological tests for 
Chlamydia, Mycoplasma, hepatitis B and C, HIV, and 
syphilis. 
Laboratory findings at the time of admission revealed 
neutrophilia and lymphopenia, a low red blood cell count, 
a low hematocrit, macrocytosis, and a normal erythrocyte 
sedimentation rate. The coagulation workup showed a 
prolonged prothrombin time. The patient’s biochemical 
tests evidenced an aspartate aminotransferase (ALT) level 
slightly above the upper limit, increased gamma-glutamyl 
transferase, a low plasma iron level, hypoproteinemia, and 
elevated C-reactive protein. Urinalysis showed a low urine 
density and the presence of urobilinogen in the sample. 
Blood samples for hemocultures were also collected and 
came back negative. 
Abdominal sonography showed hepatomegaly. Chest 
radiography revealed a 2/2 cm cavity in the right lung, 
suggestive of an old TB lesion, and also raised the 
suspicion of interstitial pneumonia. Electrocardiography 
evidenced sinus tachycardia. The transthoracic 
echocardiogram results raised the suspicion of mitral valve 
vegetation, so we referred the patient for a transesophageal 
echocardiogram. The echocardiogram also revealed 
pulmonary valve, mitral valve, and tricuspid valve 
regurgitations. Neck ultrasound showed the presence of 
round and hypoechoic lymphadenopathy. 
The suspicion of DRESS syndrome caused by 
carbamazepine was raised based on clinical examination, 
laboratory tests, and imaging investigations, and the patient 
was referred to a dermatologist. During physical 
examination, besides the rash, the doctor also identified 
enlarged lymph nodes in the inguinal area. The 
dermatologist confirmed our suspicion of DRESS 
syndrome and recommended treatment with prednisone 1 
mg/kg, emollient cream, and a number of laboratory tests 
including hepatitis C antibodies, HBs antigen, and also 
tests for Epstein-Barr virus, cytomegalovirus, and herpes 
simplex virus. The doctor also recommended cessation of 
carbamazepine administration and monitoring of renal 
function and blood cell count.  
Carbamazepine was immediately withdrawn and no 
other anticonvulsants were administered. Treatment with 
peroral prednisone 1 mg/kg and symptomatic medication 
was administered. We also monitored our patient’s blood 
cell count, renal function, blood pressure, heart rate, body 
temperature, and oxygen saturation. 
During the following weeks, the patient’s 
maculopapular exanthema progressed towards exfoliative 
erythroderma, with marked exfoliative facial dermatitis 
(Figure 1). 
 
Figure 1. Exfoliative facial dermatitis: marked 
erythema and fissures of the facial skin 
The laboratory tests improved until the third week of 
hospitalization, when new complete blood count 
alterations with leukocytosis (14.02x109 /L) and extensive 
eosinophilia (3.93x109 /L) were found. The biochemical 
tests revealed low total proteins and the urine tests showed 
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proteinuria. It was also observed that CK-MB levels were 
slightly above the upper limit. Taking into consideration 
the high eosinophil count, we performed a parasitological 
stool examination, which detected no parasite eggs or 
cysts. The eosinophil levels remained high for 
approximately one week. We continued the treatment 
recommended by the dermatologist, and the patient’s 
health and laboratory tests improved.  
After 4 weeks of hospitalization, our patient was 
released with no symptoms and improved laboratory tests, 
and we prescribed prednisone 25 mg/day (with gradually 
decreasing doses by 5 mg per week), and emollients for his 
face, thorax and hands. We also recommended avoiding 
anticonvulsants such as carbamazepine, phenytoin, 
phenobarbital, or other medications associated with 
DRESS syndrome.   
Discussions 
DRESS syndrome is a severe, potentially fatal, 
idiosyncratic adverse drug reaction [1]. Classical diagnosis 
is based on skin lesions, fever, and eosinophilia. Rash is the 
most common feature of this disease and is present in 73-
100% of patients. The pattern of the lesions varies from one 
patient to another. Typically, they involve more than 50% 
of the body surface and have a polymorphic presentation 
such as infiltrative papules, plaques which resemble 
urticarial, target-like or eczema-like lesions [7, 8]. Facial 
edema is present in 76% of cases. Regarding organ 
damage, the liver (75%), kidneys (37%), and lungs (32%) 
are frequently affected [9]. There are atypical presentations 
of DRESS syndrome with cardiac, neurologic, 
gastrointestinal, and endocrine manifestations [1]. Our 
patient presented all the classic clinical features of this 
syndrome, with important facial edema that disfigured his 
physiognomy. In addition, the patient had mucosal 
involvement with pharyngeal erythema. Mucosal 
membranes are often affected by this disease [5].  
Enlarged lymph nodes are also present in 54% of the 
patients. They can be a clinical finding or revealed by 
imaging [7]. In our patient, lymph node involvement was 
identified both by physical examination and neck 
ultrasonography. 
Risk factors for renal involvement in DRESS syndrome 
include old age and a medical history of kidney disease or 
cardiovascular diseases [7]. In our patient, the kidney 
injury manifested as proteinuria, but his renal function 
recovered completely. Kidney involvement is most 
commonly seen in DRESS syndrome caused by 
administration of allopurinol, followed by carbamazepine 
[1]. 
Pulmonary involvement in DRESS syndrome is not 
only defined by clinical findings (cough, dyspnea), but also 
by chest X-ray. The most common imaging sign of lung 
injury is interstitial pneumonitis [10]. Our patient’s chest 
radiography raised the suspicion of interstitial lung injury, 
but without any clinical signs of respiratory symptoms. 
Eosinophilia was absent in the first 3 weeks of 
hospitalization and registered high values only on the 23rd 
day after admission. It is well known that eosinophilia is 
often absent initially in DRESS syndrome [5]. The white 
blood cell count tests in the reported patient are presented 
in Table I. 
 
Table I. White blood cell count tests in the reported patient 
Laboratory parameter  Day 1 Day 2 Day 4 Day 8 Day 23  Day 28 
WBC (10∧3/ul) 5.21 6.75 9.40 16.51 14.02 14.36 
EO% 0.0 0.0 1.1 0.4 28.0 18.7 
EO# (10∧3/ul) 0.00 0.00 0.10 - 3.93 2.69 
WBC white blood cell count, EO eosinophils 
In our case, the culprit drug was carbamazepine. 
Aromatic anticonvulsants (phenytoin, carbamazepine, 
phenobarbital) are metabolized by cytochrome P450 with 
the formation of toxic reactive metabolites, which under 
physiological conditions are converted by epoxide 
hydroxylase or glutathione transferase to non-toxic 
components. If these pathways are deficient, the 
accumulation of toxic metabolites results in altered 
immune responses and cellular damage [11]. Ampicillin, 
another drug known to cause DRESS syndrome, was 
administered to the patient [7]. The relationship between 
the antibiotic and the pathogenesis of this idiosyncratic 
reaction was excluded by the short time interval between 
drug administration and symptom onset. 
For the diagnosis of DRESS syndrome, we applied the 
RegiSCAR criteria for hospitalized patients and the 
Japanese Group score, used in the diagnosis of drug-
induced hypersensitivity. Thus, the case was categorized as 
definite DRESS syndrome with a score of 7, atypical 
DRESS syndrome, respectively [12]. The RegiSCAR 
scoring and the Japanese Group scoring for diagnosis of 
DRESS syndrome and our case estimations are presented 
in Table II and Table III. 
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Table II. RegiSCAR scoring system for diagnosis of DRESS syndrome and our case estimation [12]. 
CRITERIA SCORE 
 NO YES UNKNOWN CASE SCORE 
Fever ≥38.5°c -1 0 -1 0 
Enlarged lymph nodes ≥2 sites and >1cm 0 1 0 1 
Peripheral eosinophilia  
• 0.7-1.5x109/l or 10-19.9% 












Atypical lymphocytes 0 1 0 0 
Skin involvement  
• Extent of cutaneous eruption ≥50%  
• Skin rash suggesting DRESS 





























Resolution ≥15 days -1 0 -1 0 
Laboratory results negative for at least 3 of the 
following 
• ANA, blood culture, HAV/HBV/HCV 









Total score <2 no case; 2-3 possible case; 4-5 probable case; >5 definite  7 
 
Table III. Japanese Group scoring system for diagnosis of DRESS syndrome and our case estimation [12]. 
CRITERIA           CASE SCORE  
Maculopapular rash developing >3 weeks after drug initiation 1 
Clinical symptoms continuing >2 weeks after stopping therapy 1 
Fever >38°C 1 
Liver abnormalities (ALT>100 IU/L) or other organ involvement 1 
Hematological abnormalities 
• Leukocytosis 




Human herpes 6 reactivation 0 
7=typical DRESS syndrome; 5=atypical DRESS syndrome;  
<5 consider other diagnosis 
6 
ALT Alanine transaminase 
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The diagnosis of DRESS syndrome requires a high 
level of suspicion, and differential diagnosis includes a 
large number of maladies such as infectious diseases 
(especially viral exanthema, particularly EBV infectious 
mononucleosis) [7], graft versus host disease [13], 
autoimmune diseases (Still’s disease, Kawasaki disease), 
and neoplastic diseases [14]. The presence of neoplasia, 
infections, or collagenosis in our patient was excluded 
following imaging investigations and clinical 
consultations [3]. 
The appropriate treatment of DRESS syndrome is 
mainly supportive and symptomatic. The first step in the 
management of this disease is prompt withdrawal of the 
culprit drug. In case of organ involvement, the use of 
systemic corticosteroids (1 mg/kg/day) is recommended. If 
there is renal or lung injury, systemic glucocorticoid 
therapy is necessary until the clinical signs and the 
laboratory investigations normalize. Sometimes, pulsed 
methylprednisolone therapy is required [3]. If organ 
involvement is severe and life-threatening, intravenous 
immunoglobulin therapy should be associated with 
systemic corticosteroids [5]. In resistant cases, 
plasmapheresis could be a therapeutic option [15]. If 
corticotherapy is not efficient, cyclosporine can be used as 
a second line option in DRESS syndrome cases with severe 
organ involvement [3]. When virus reactivation is 
demonstrated, ganciclovir may be given in addition to 
intravenous globulin and systemic corticosteroids, but the 
efficiency of antiviral drugs in DRESS syndrome is not 
well documented [5]. In patients with exfoliative 
dermatitis, maintaining the skin barrier and proper 
hydration are essential to adequate management. 
Symptomatic treatment consists of emollients, topical 
corticosteroids, and antihistamines. After DRESS 
syndrome diagnosis, in our case, the first therapeutic step 
was to stop the administration of carbamazepine. The 
treatment we gave to our patient consisted of oral 
corticosteroids (prednisone 1 mg/kg), intravenous fluids, 
and symptomatic medication (H1-antihistamines for relief 
of pruritus).  
Recovery of DRESS syndrome patients occurs 
gradually and takes weeks or even months [3]. Our patient 
fully recovered after 4 weeks of hospitalization. The 
evolution of these patients is marked by flare-ups even 
after using structurally different drugs. In case of 
reoccurrence, the most frequent findings are skin rashes 
and cell blood count abnormalities with eosinophilia [7]. 
The long-term sequelae of DRESS syndrome include 
autoimmune phenomena (autoimmune thyroid disease, 
type 1 diabetes mellitus, systemic sclerosis, and systemic 
lupus erythematosus) [16]. Taking into consideration the 
morbidity of these patients, careful follow-up is essential 
in order to identify recurrences or the development of 
autoimmune diseases. In our patient’s case, during follow-
up until now, there have been no recurrences of DRESS 
syndrome or manifestations of autoimmunity. 
Conclusions 
In patients with DRESS syndrome, early diagnosis and 
prompt intervention may improve outcomes. The diagnosis 
of this syndrome is often delayed due to polymorphic 
manifestations and to the long time period between 
administration of the culprit drug and symptom onset. 
Physicians should always keep in mind that the basic step 
in the disease management is immediate discontinuation of 
the suspected drug. Our case represents a DRESS 
syndrome induced by carbamazepine, an aromatic 
anticonvulsant. Our patient exhibited common signs and 
symptoms: morbilliform rash, fever, and eosinophilia. 
Apart from cutaneous manifestations, organ involvement 
was present with renal and pulmonary injury. Our case 
attempts to increase awareness of DRESS syndrome 
among physicians and to emphasize the importance of 
early diagnosis and treatment. We also aim to highlight the 
value of a multidisciplinary approach and proper follow up, 
which is crucial for the long-term prognosis of DRESS 
syndrome patients.  
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